Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals — Investor Presentation (March 2021)

28 slides from Dicerna Pharmaceuticals's investor presentation, Mar 2, 2021

  1. Slide 1: Corporate Overview: Discovery to Commercialization RNAi Platform

    Corporate Overview Discovery to Commercialization RNAi Platform March 2021

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materi

  3. Slide 3: Dicerna was founded to specialize in RNAi

    Dicerna was founded to specialize in RNAi Partner of Choice: Several large pharmas have chosen Dicerna for RNAi collaboration The RNAi Modality Has Come of Age RNAi Has Been Successful Where Traditional Modalities Have Not 3 Gene Targeting Across Multiple Tissue Types Approved Products in Multiple D

  4. Slide 4: RNAi Delivery Is Extending to Multiple Tissues Beyond the Liver

    RNAi Delivery Is Extending to Multiple Tissues Beyond the Liver The Future Is Bright 4 Alzheimer’s, Parkinson’s, frontotemporal dementia, Huntington’s, spinal cord injury, other rare diseases and more Immuno-oncology Diabetes, obesity, rare diseases and more Diseases of the lung, eye, kidney, etc. M

  5. Slide 5: Dicerna Is an Engine of Discovery and Development

    Dicerna Is an Engine of Discovery and Development Core Clinical Pipeline Current pipeline yields multiple major milestones over next year+ • Nedosiran: A differentiated potential therapy for all primary hyperoxaluria (PH) types (PH1, PH2 and PH3) • RG6346: Potential best-in-class therapeutic with st

  6. Slide 6: Core and Collaborative Development-Stage Programs

    With 20+ discovery-stage programs in multiple tissues Core and Collaborative Development-Stage Programs Ten Programs Have Entered Development, Many More Are in Discovery Stage 6 TARGET INDICATION COMPOUND (GENE TARGET) PRECLINICAL EARLY CLINICAL TRIALS REGISTRATION TRIALS DICERNA PRODUCT RIGHTS PART

  7. Slide 7: GalXC-Plus builds on GalXC's favorable characteristics

    GalXC-Plus builds on GalXC’s favorable preclinical and clinical characteristics + additional remarkable flexibility for medicinal chemistry optimization and expansion into new therapeutic areas GalXC RNAi technology offers excellent pharmacological properties to de-risk development • Sequence-specif

  8. Slide 8: Key Value Drivers

    Key Value Drivers • Core Clinical Programs ‒ Nedosiran for primary hyperoxaluria (PH) ‒ RG6346 for chronic hepatitis B virus (HBV) ‒ Belcesiran for alpha-1 antitrypsin deficiency-associated liver disease (AATLD) ‒ DCR-AUD for alcohol use disorder (AUD) • Collaborative Programs ‒ Roche and Novo opt-i

  9. Slide 9: Nedosiran for the Treatment of Primary Hyperoxaluria (PH)

    Nedosiran for the Treatment of Primary Hyperoxaluria (PH)

  10. Slide 10: The Disease: Primary Hyperoxaluria

    The Disease: Primary Hyperoxaluria A Family of Ultra-Rare, Life-Threatening Genetic Disorders Resulting in Renal Complications GO = glycolate oxidase LDHA = lactate dehydrogenase A CKD= chronic kidney disease ESRD= end-stage renal disease 10 Kidney function preservation Kidney stones Impacted by ESR

  11. Slide 11: The Opportunity: Nedosiran Is the Only RNAi Drug Candidate for All PH Types

    The Opportunity: Nedosiran Is the Only RNAi Drug Candidate for All PH Types Planned Commercial Launch in 1H 2022 11 comprehensive treatment option for all patients with PH Education Estimated PH Diagnosis Rates PH1 PH2 PH3 Current Diagnosis Projections^ ~40% – 50% ~10% ~7% Diagnostic Testing Patient

  12. Slide 12: The Data: Average Oxalate Levels Normalized After Nedosiran Treatment

    The Data: Average Oxalate Levels Normalized After Nedosiran Treatment Results From Ongoing Multidose Open-Label PHYOX™3 Trial 12 *One participant was missing Uox value at Day 60; BSA = body surface area adjusted; Uox = urinary oxalate Nedosiran was generally well tolerated, and no serious safety con

  13. Slide 13: The Plan: Building Dicerna's Commercial Infrastructure

    The Plan: Building Dicerna’s Commercial Infrastructure Striving for Best-in-Class Service to the PH Community 13 Serving a rare disease community requires long-term comprehensive commitment and dedication Education Disease education for HCPs, payors and patients on all aspects of PH • Medical Scienc

  14. Slide 14: RG6346 for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

    RG6346 for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

  15. Slide 15: The Disease: Chronic HBV Is a Severe, Global Unmet Medical Need

    The Disease: Chronic HBV Is a Severe, Global Unmet Medical Need • Significant worldwide prevalence: ~292 million infected, >880,000 deaths per year • Current treatments are rarely effective in achieving functional cures • Collaborating with • Roche to conduct Phase 2 combination clinical studies wit

  16. Slide 16: The Data: Reductions in HBsAg Levels Ongoing One Year After Last Dose

    Mean HBsAg log10 IU/mL Change From Baseline The Data: Reductions in HBsAg Levels Ongoing One Year After Last Dose NUC-Suppressed Chronic HBV Participants (Group C) Given 4 Monthly Doses 16 • 1.8 log10 mean reduction (IU/ml) of hepatitis B surface antigen (HBsAg) (3 mg/kg and 6 mg/kg cohorts) • 2.7 l

  17. Slide 17: Belcesiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    Belcesiran for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease (AATLD)

  18. Slide 18: Belcesiran for AATLD: Significant Opportunity in a Rare Genetic Condition

    Belcesiran for AAT Deficiency-Associated Liver Disease (AATLD) Significant Opportunity In a Rare, Genetic Condition That Can Lead to Liver Disease • Z-allele of SERPINA1 gene produces abnormal AAT protein that may lead to chronic liver disease culminating in cirrhosis, liver failure, cancer. No avai

  19. Slide 19: DCR-AUD for the Treatment of Alcohol Use Disorder (AUD)

    DCR-AUD for the Treatment of Alcohol Use Disorder (AUD)

  20. Slide 20: The Impact and Opportunity

    The Impact and Opportunity • AUD: A disorder characterized by the inability to stop or control alcohol use despite social, occupational or health consequences • ~95,000 deaths each year in U.S. due to alcohol-related causes A New Potential Therapeutic Approach to Treating AUD • DCR-AUD is designed t

  21. Slide 21: Corporate Collaborations

    Corporate Collaborations

  22. Slide 22: Successfully Executing on High-Value Collaboration Strategy

    Successfully Executing on High-Value Collaboration Strategy • Broad therapeutic areas including rare and common diseases: cardiovascular disease, NASH, cardiometabolic diseases, etc. • First collaborative program entered clinic Q4 2020 • Expect 2-3 clinical entries in 2021 • >20 discovery and precli

  23. Slide 23: GalXC-Plus Extrahepatic Platform

    Ga XC Plus” Extrahepatic Platform Dicerna

  24. Slide 24: Broad Opportunity in Tissues Beyond the Liver

    : Broad Opportunity in Tissues Beyond the Liver Future Pipeline and Collaborations to Include Delivery Beyond Liver 24 Dicerna TIDES Europe Presentation, Nov. 10, 2020 100% owned technology Up to 99% gene silencing in non-human primate models from a single dose Rare diseases and large-market neurode

  25. Slide 25: Management Team

    Management Team Leading Experts in RNAi Technology, Clinical, Regulatory and Commercial Operations 25 Douglas M. Fambrough, Ph.D. President and Chief Executive Officer Douglas Pagán Chief Financial Officer Rob Ciappenelli Chief Commercial Officer Shreeram Aradhye, M.D. EVP, Chief Medical Officer Bob

  26. Slide 26: Strong Balance Sheet

    Strong Balance Sheet Dicerna’s Business Model Has Potential to Fund Robust Pipeline Growth Expect balance sheet to remain strong due to product revenue, payments from existing collaborations, new collaborations, and asset monetization (does not include any proceeds from potential follow-on stock off

  27. Slide 27: Target Milestones To Drive Momentum in 2021

    Target Milestones To Drive Momentum in 2021 Focused on Execution 27 • Nedosiran for PH (PH1, PH2, PH3)  Complete pivotal enrollment  Top-line PHYOX2 pivotal data mid-year 2021  PHYOX4 data in PH3 mid-year 2021  NDA submission Q3 2021  Prepare for 2022 target launch • RG6346 for HBV  Phase 2 st

  28. Slide 28: Slide 28

Dicerna Pharmaceuticals — Investor Presentation (March 2021) on 6ix